Swiss National Bank Grows Stock Position in Revvity Inc. $RVTY

Swiss National Bank lifted its holdings in Revvity Inc. (NYSE:RVTY) by 5.9% during the second quarter, Holdings Channel reports. The institutional investor owned 363,700 shares of the company’s stock after purchasing an additional 20,400 shares during the quarter. Swiss National Bank’s holdings in Revvity were worth $35,177,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. UMB Bank n.a. lifted its holdings in Revvity by 138.8% in the 2nd quarter. UMB Bank n.a. now owns 406 shares of the company’s stock valued at $39,000 after purchasing an additional 236 shares in the last quarter. CVA Family Office LLC increased its position in Revvity by 79.0% during the 2nd quarter. CVA Family Office LLC now owns 410 shares of the company’s stock worth $40,000 after purchasing an additional 181 shares in the last quarter. New Age Alpha Advisors LLC acquired a new position in shares of Revvity during the 1st quarter valued at $44,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Revvity by 25.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 694 shares of the company’s stock worth $73,000 after buying an additional 140 shares during the period. Finally, Cary Street Partners Investment Advisory LLC purchased a new stake in shares of Revvity during the first quarter valued at approximately $75,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Stock Performance

Shares of RVTY stock opened at $100.49 on Tuesday. Revvity Inc. has a 12-month low of $81.36 and a 12-month high of $128.29. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.75 and a quick ratio of 2.75. The firm has a market capitalization of $11.39 billion, a price-to-earnings ratio of 50.50, a price-to-earnings-growth ratio of 3.15 and a beta of 1.01. The business has a 50 day simple moving average of $91.76 and a 200 day simple moving average of $92.34.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, October 27th. The company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.04. The company had revenue of $698.95 million for the quarter, compared to analysts’ expectations of $699.75 million. Revvity had a return on equity of 7.52% and a net margin of 8.44%.The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period last year, the firm earned $1.28 EPS. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS. On average, equities research analysts anticipate that Revvity Inc. will post 4.94 EPS for the current year.

Revvity declared that its Board of Directors has approved a stock repurchase program on Monday, October 27th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 8.7% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 6th. Stockholders of record on Friday, January 16th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, January 16th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s dividend payout ratio is 14.07%.

Analyst Ratings Changes

RVTY has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Revvity from a “buy” rating to a “hold” rating in a research note on Sunday, August 3rd. Barclays boosted their target price on shares of Revvity from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 28th. Bank of America cut their target price on shares of Revvity from $110.00 to $99.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Revvity in a research note on Wednesday, November 19th. Finally, Guggenheim started coverage on shares of Revvity in a research note on Wednesday, October 15th. They set a “neutral” rating for the company. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $114.75.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.